CTI BioPharma Corp. (NASDAQ:CTIC) is among the top stocks that may remain in focus today as the company shares are trading 5.72% or 0.05 points higher from last closing price of $0.87, reaching $0.9198 at last check. Any clue why there is so much of action in the CTIC stock? The share price has risen in 4 of the last 5 days and is down -13.86% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 81,422 shares, and in total 170222 shares valued at $156570 were seen changing hands compared with 88800 shares valued at $77256 recorded at the previous session. You should take into consideration that a greater volume on higher prices causes bullish signal for the market. It shows the sentiment is in an uptrend and more and more traders want to enter in the CTIC stock.
CTI BioPharma Corp. (CTIC) shares have notched a 3-month decline of about -13.86%, but has still advanced 18.59% year to date. By comparison, the stock sank -82.28% over the past 12 months, while it jumped 2.59% over the 1 month. The company’s market cap is around $51.86M, with its short interest ratio standing at 8.74%.
In the current trading session for CTIC, the stock witnessed two major price actions, it rose to a high of $0.92 and was down as much as $0.86 at one point. The high recorded is very low when compared to their 52-week high which is $0.6. The 52-week high is now at -82.93 distance from current price. Their recent low of $5.36 represents a 52.49% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for CTIC is $5.33, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of CTI BioPharma Corp. earned $-0.62 per share in the trailing 12 months and has a P/E ratio of -1.48. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 105.27 and lower compared to the sector’s average of 37.46. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. CTIC also has P/S multiple of 3.32. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 43.04x.
The company recorded an interesting insider purchase transaction by the Major Shareholder on Feb 09, 2018. A Securities and Exchanges Commission filings show that Bvf Partners L P/Il bought a total of 5,634,108 CTIC shares that day for a sum of around $16,902,324. CTI BioPharma Corp. (CTIC) insiders have acquired no shares in the stock within the past three months. In total, individual insiders traded no shares in the business, which makes up 0% of 1,000 shares that were traded over a year. In the past 12 months, insiders have purchased 1,000 shares while the seller parted with shares.
CTIC‘s last price was down -30.22% as compared to the average trading price of 50 days recorded at $1.32 while enlarging the period to 200 trading days, the average closing price was $0.92. At present, there are 59.61 million in the total number of common shares owned by the public and among those 57.69 million shares have been available to trade. The percentage of shares being held by the company management was 0.1% while institutions stake was 53.6%. The company has generated negative returns on equity over the last 12 months (-61.3%). It managed to keep its gross profit margin at 95.2% over the past 12 months.
When assessing the full upside of the CTIC stock, there is another set of technicals that should be looked into and considered. Its 8.7% gain from moving average of $0.85 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 1.61 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of CTI BioPharma Corp. — 4 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $5 on shares of CTI BioPharma Corp. (NASDAQ:CTIC), which corresponds to 474.71% upside potential than its current market price of $0.9198 and implies potential despite the recent advance in the price. However, their current target price has fallen from $5 a month ago and is down handily from the consensus target of $6 a quarter ago.
In the last five years, the EPS of the company has been roughly 34.5%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about -5.4 over the last five years. The company recently recorded a drop of -94.4%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards CTIC stock. Oxford Asset Management LLP added position in the company after it grew 174.7% or 38,364 shares of its common stock. The hedge fund now owns 105,385 shares worth $96,933, SEC documents show. Renaissance Technologies LLC shored up assets in the stock as 1132820 shares have been purchased, increasing its stake by 13.2% to 1,282,352 shares which are currently valued at $1,179,507. In addition, State of Wisconsin Investment Board recently reported that it now owns 68,400 shares making a total of $62,914 based on the recent price. This refelects a change of 18.7% in their ownership.